(2022) Adherence to the "Atrial fibrillation Better Care" (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry. European Journal of Internal Medicine. pp. 54-62. ISSN 1879-0828 (Electronic) 0953-6205 (Linking)
Full text not available from this repository.
Abstract
BACKGROUND: Implementation of the Atrial fibrillation Better Care (ABC) pathway is recommended by guidelines on atrial fibrillation (AF), but the impact of adherence to ABC pathway in patients with cancer is unknown. OBJECTIVES: To investigate the adherence to ABC pathway and its impact on adverse outcomes in AF patients with cancer. METHODS: Patients enrolled in the EORP-AF General Long-Term Registry were analyzed according to (i) No Cancer; and (ii) Prior or active cancer and stratified in relation to adherence to the ABC pathway. The composite Net Clinical Outcome (NCO) of all-cause death, major adverse cardiovascular events and major bleeding was the primary endpoint. RESULTS: Among 6550 patients (median age 69 years, females 40.1), 6005 (91.7) had no cancer, while 545 (8.3) had a diagnosis of active or prior cancer at baseline, with the proportions of full adherence to ABC pathway of 30.6 and 25.7, respectively. Adherence to the ABC pathway was associated with a significantly lower occurrence of the primary outcome vs. non-adherence, both in 'no cancer' and 'cancer' patients adjusted Hazard Ratio (aHR) 0.78, 95% confidence interval (CI): 0.66-0.92 and aHR 0.59, 95% CI 0.37-0.96, respectively. Adherence to a higher number of ABC criteria was associated with a lower risk of the primary outcome, being lowest when 3 ABC criteria were fulfilled (no cancer: aHR 0.54, 95%CI: 0.36-0.81; with cancer: aHR 0.32, 95% CI 0.13-0.78). CONCLUSION: In AF patients with cancer enrolled in the EORP-AF General Long-Term Registry, adherence to ABC pathway was sub-optimal. Full adherence to ABC-pathway was associated with a lower risk of adverse events.
Item Type: | Article |
---|---|
Keywords: | Female Humans Aged *Atrial Fibrillation/epidemiology *Stroke/epidemiology Risk Factors Registries Hemorrhage/chemically induced Anticoagulants/adverse effects *Neoplasms/complications Atrial fibrillation Cancer Integrated care Mortality Outcomes Stroke Boehringer Ingelheim and Daiichi, outside the submitted work. LF: Consultant or speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis and XO. FM: Advisor fees Boehringer-Ingelheim, Research Grants Ferrer, Speaker fees Boehringer-Ingelheim, Astra-Zeneca, Pfizer and Bayer TP: Consultant for Bayer and Pfizer (no fees). GAD: Small speaker fees from Boehringer-Ingelheim, Pfizer, Bayer, Sanofi and Zentiva DAL has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS), has been a speaker for Bayer, Boehringer Ingeheim, and BMS/Pfizer and has consulted for BMS, and Boehringer Ingelheim. GYHL: Consultant and speaker for Bayer/Janssen, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo (No fees are directly received personally). All the disclosures occurred outside the submitted work. Other authors have no disclosures to declare |
Page Range: | pp. 54-62 |
Journal or Publication Title: | European Journal of Internal Medicine |
Journal Index: | Pubmed |
Volume: | 105 |
Identification Number: | https://doi.org/10.1016/j.ejim.2022.08.004 |
ISSN: | 1879-0828 (Electronic) 0953-6205 (Linking) |
Depositing User: | خانم ناهید ضیائی |
URI: | http://eprints.mui.ac.ir/id/eprint/24177 |
Actions (login required)
![]() |
View Item |